Acerus Signs License Agreement to Nasal Technology with University of Texas at Austin

TORONTO–(BUSINESS WIRE)–Acerus Pharmaceuticals Corporation (“Acerus” or “the Company”) (TSX:ASP;
OTCQB:ASPCF) announced today that it has signed a patent license
agreement (the “PLA”) with the University of Texas at Austin for
technology related to the nasal administration of testosterone. The
newly patented, aqueous-based, nasal delivery technology was developed
by Robert Josephs, a UT Austin Professor of Clinical and Social
Psychology, and Craig Herman, a Doctor of Pharmacy at MedCara
Pharmaceuticals in Conrad, Iowa. Under the PLA, Acerus has licensed
worldwide exclusive rights to this technology in all applicable fields.

“We are pleased to have partnered with UT Austin and Professor Josephs
for the development of this technology,” said Ed Gudaitis, President &
CEO of Acerus. We expect that this new technology will allow us to
develop therapeutic options that will complement our existing nasal
technology. Acerus’ expertise in the formulation and development of
nasally delivered active pharmaceutical ingredients, and more
particularly testosterone, should enable Acerus to make this new
technology a success.”

About Acerus Pharmaceuticals Corporation

Acerus Pharmaceuticals Corporation is a Canadian-based specialty
pharmaceutical company focused on the commercialization and development
of innovative, pharmaceutical products that improve patient experience,
with a primary focus in the field of men’s health. The Company
commercializes its products via its own salesforce in Canada, and
through a global network of licensed distributors in the U.S. and other
territories.

In addition to the listing on OTCQB, Acerus’ shares trade on TSX under
the symbol ASP. For more information, visit www.aceruspharma.com
and follow us on Twitter
and LinkedIn.

Forward-Looking Information

Information in this press release that is not current or historical
factual information may constitute forward-looking information within
the meaning of securities laws. Implicit in this information are
assumptions regarding our future operational results. These assumptions,
although considered reasonable by the company at the time of
preparation, may prove to be incorrect. Readers are cautioned that
actual performance of the company is subject to a number of risks and
uncertainties, including with respect to the future performance of the
UT Austin in-licensed technology or its suitability in clinical trials,
and could differ materially from what is currently expected as set out
above. For more exhaustive information on these risks and uncertainties
you should refer to our annual information form dated March 4, 2019 that
is available at www.sedar.com.
Forward-looking information contained in this press release is based on
our current estimates, expectations and projections, which we believe
are reasonable as of the current date. You should not place undue
importance on forward-looking information and should not rely upon this
information as of any other date. While we may elect to, we are under no
obligation and do not undertake to update this information at any
particular time, whether as a result of new information, future events
or otherwise, except as required by applicable securities laws.

Contacts

Edward Gudaitis
President & CEO
Acerus Pharmaceuticals
Corporation
[email protected]
905-817-8194